Search results
Results from the WOW.Com Content Network
Federal mandates. In September 2021, Biden announced the Biden administration COVID-19 action plan, a six-point plan of new measures to help control the pandemic, which included new executive orders and regulatory actions to effectively mandate vaccination for COVID-19 among a large swath of the American workforce.
States, territories, and counties that issued a stay-at-home order in 2020. State, territorial, tribal, and local governments responded to the COVID-19 pandemic in the United States with various declarations of emergency, closure of schools and public meeting places, lockdowns, and other restrictions intended to slow the progression of the virus.
As of November 2022, according to The Commonwealth Fund, COVID-19 vaccination in the United States has prevented an additional 3.2 million deaths, an additional 18.5 million hospitalizations, and an additional 120 million infections from COVID-19. Vaccination has also prevented an additional $899.4 billion in healthcare costs. [22]
April 11, 2024 at 1:09 PM. (Reuters) -Moderna said on Thursday it had paused its plans to build a vaccine manufacturing facility in Kenya, following a post-pandemic decline in demand for COVID-19 ...
During the COVID-19 pandemic, several COVID-19 vaccines were developed, and in December 2020 the first vaccination campaign was planned. Anticipating the vaccine, on 23 November 2020, Qantas announced that the company would ask for proof of COVID-19 vaccination from international travellers. According to Alan Joyce, the firm's CEO, a ...
National regulatory authorities have granted full or emergency use authorizations for 40 COVID-19 vaccines. Ten vaccines have been approved for emergency or full use by at least one stringent regulatory authority recognized by the World Health Organization (WHO): Pfizer–BioNTech, Oxford–AstraZeneca, Sinopharm BIBP, Moderna, Janssen, CoronaVac, Covaxin, Novavax, Convidecia, and Sanofi–GSK ...
Gritstone bio started in 2021 a phase 1 trial of an saRNA COVID-19 vaccine, used as a booster vaccine. The vaccine is designed to target both the spike protein of the SARS‑CoV‑2 virus, and viral proteins that may be less prone to genetic variation, to provide greater protection against SARS‑CoV‑2 variants.
The COVID-19 pandemic in Kenya was a part of the worldwide pandemic of coronavirus disease 2019 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus was confirmed to have reached Kenya on 12 March 2020, [3] with the initial cases reported in the capital city Nairobi and in the coastal area Mombasa .